Harbour BioMed (HKG: 2142), a biotech with operations in the United States, the Netherlands, and Suzhou (China), has announced a partnership with UK major AstraZeneca (AZ, NASDAQ: AZN). The collaboration aims to advance the construction of a pharmaceutical industry innovation alliance in the Yangtze River Delta region, strengthen global collaboration on research and development platforms and novel drugs, and explore investment opportunities within the industry.
Building on a Strong Foundation
The partnership between Harbour BioMed and AstraZeneca is built on an existing relationship that was established in 2022. At that time, Harbour granted AstraZeneca global rights to its HBM7022, a bispecific antibody (BsAb) targeting CLDN18.2 and CD3, through a licensing deal valued at USD 350 million. This deal highlighted the potential for further collaboration between the two companies.
Enhancing Global R&D and Investment in the Pharmaceutical Sector
The new partnership seeks to leverage the strengths of both companies to enhance global research and development efforts and identify new investment opportunities in the pharmaceutical industry. By focusing on the Yangtze River Delta region, the alliance aims to foster innovation and drive forward the development of novel drugs and therapies.-Fineline Info & Tech
